C7orf28B Activators
C7orf28B Activators are a diverse set of chemical compounds that indirectly enhance the functional activity of C7orf28B by manipulating various signaling pathways that converge on the modulation of this protein. Forskolin and Isoproterenol, through their ability to increase intracellular cAMP levels, activate protein kinase A (PKA), which may phosphorylate substrates that influence the activity of C7orf28B, thus enhancing its function within cellular signaling networks. Similarly, the calcium ionophore Ionomycin and Thapsigargin, which disrupts calcium homeostasis, can lead to the activation of calmodulin-dependent kinases that could subsequently elevate the activity of C7orf28B by altering its phosphorylation state or that of associated proteins. The bioactive lipid Sphingosine-1-phosphate (S1P) engages with cell surface receptors to activate downstream MAPK and PI3K/Akt pathways, potentially enhancing C7orf28B's role in cellular processes like growth and survival. Phorbol 12-myristate 13-acetate (PMA) serves as a direct activator of protein kinase C (PKC), and its activation may enhance C7orf28B activity through targeted phosphorylation events within the associated signaling pathways.
Additionally, the polyphenol Epigallocatechin gallate (EGCG) is known to activate AMP-activated protein kinase (AMPK), which may indirectly enhance C7orf28B activity by affecting the protein's involvement in energy balance and metabolic pathways. The PI3K inhibitor LY294002, although it inhibits a key signaling molecule, could indirectly enhance C7orf28B activity by shifting the equilibrium of signaling cascades that C7orf28B is part of. U0126, a MEK inhibitor, might allow for the indirect enhancement of C7orf28B activity by changing the phosphorylation landscape within the MAPK pathway, potentially favoring C7orf28B-associated functions. Conversely, Bisindolylmaleimide I, as a PKC inhibitor, could lead to a compensatory enhancement of C7orf28B activity through the activation of alternative signaling pathways. Anisomycin's role in activating stress-activated protein kinases could also lead to the enhancement of C7orf28B activity through stress response pathways. Collectively, these activators manipulate a variety of signaling networks to promote the functional activity of C7orf28B, demonstrating the complex interplay of different cellular mechanisms in regulating protein function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that raises intracellular calcium levels by facilitating the influx of calcium ions. Increased intracellular calcium can activate calmodulin-dependent kinase pathways, which could then enhance the activity of C7orf28B by modifying the phosphorylation state or the activity of proteins that are part of the C7orf28B functional complex. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). Activation of PKC leads to phosphorylation of target proteins and can enhance the activity of C7orf28B by modulating the protein-protein interactions or phosphorylation status of components within the C7orf28B-related signaling pathways. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P is a bioactive lipid that activates sphingosine-1-phosphate receptors, leading to downstream activation of MAPK and PI3K/Akt pathways. This activation can indirectly enhance C7orf28B activity by modulating cellular processes such as growth, survival, and proliferation, in which C7orf28B might play a role. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a synthetic beta-adrenergic agonist which increases intracellular cAMP levels, similar to Forskolin. The resultant activation of PKA can lead to enhanced C7orf28B activity by phosphorylation of associated proteins or alteration of the cellular localization of C7orf28B, thereby influencing its functional role in the cell. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a sesquiterpene lactone that inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to an increase in cytosolic calcium levels. Elevated calcium can enhance C7orf28B activity through calmodulin and calcium-calmodulin-dependent kinases, which may influence the phosphorylation and function of C7orf28B. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenol found in green tea with antioxidant properties. It can modulate several signaling pathways, including activation of AMP-activated protein kinase (AMPK). Activation of AMPK can lead to enhanced C7orf28B activity by modulating energy homeostasis and metabolic processes in which C7orf28B is involved, potentially altering its activity state. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). Inhibition of PI3K can lead to changes in downstream signaling pathways such as Akt, potentially enhancing C7orf28B activity by affecting the balance of signaling networks that regulate functions associated with C7orf28B. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is part of the MAPK pathway. Inhibition of MEK may indirectly enhance the activity of C7orf28B by modulating the phosphorylation of proteins in the MAPK pathway, which can influence the overall signaling environment in which C7orf28B operates. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific PKC inhibitor. Paradoxically, inhibition of specific PKC isoforms can lead to the compensatory activation of alternative pathways that may enhance the activity of C7orf28B. This could occur through the altered phosphorylation of proteins that interact with or regulate C7orf28B, leading to its functional enhancement. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can also activate stress-activated protein kinases like JNK and p38 MAPK. Activation of these kinases may enhance C7orf28B activity | ||||||